Hsu Chih-Wei, Lee Yu, Lee Chun-Yi, Lin Pao-Yen
Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital, 123, Dapi Road, Niaosong District, Kaohsiung City 833, Taiwan.
BMC Pharmacol Toxicol. 2016 Dec 14;17(1):59. doi: 10.1186/s40360-016-0101-x.
Combination lithium, a mood stabilizer, and risperidone, an atypical antipsychotic drug, is widely used for treatment of psychotic disorders. Rare reports concern severe adverse drug reaction in multiple organic systems with their combined use. We report two episodes of neurotoxicity and nephrotoxicity in a patient following the combined use of lithium and risperidone.
A 55-year-old male had a diagnosis of schizoaffective disorder at the age of 51. He was initially treated with a combination of lithium and olanzapine 5 to 15 mg/day for 2 years. He was admitted to psychiatric ward at the age of 53 due to manic episode with psychotic feature. Because of poor blood sugar control, we switched olanzapine 20 mg/day to risperidone 4.5 mg/day with combination of lithium 900mg/day. The patient presented neurotoxicity, neuroleptic-malignant-syndrome like symptoms, and nephrotoxicity, elevation of blood creatinine and decreased urine output few days later. These signs were fully recovered within 2 days after we discontinued all medications and gave normal saline hydration. Then we re-administered decreased dosage of lithium 600 mg/day and risperidone 3 mg/day, and the similar episode occurred again 3 days later. All drugs were discontinued again, then his delirium resolved and abnormal data returned to normal 1 day later. Finally, the patient was treated with risperidone 2 mg/day as monotherapy, and no episode of neurotoxicity and nephrotoxicity appeared in the following 2 years.
The case exemplifies neurotoxicity and nephrotoxicity after combined use of lithium and risperidone. These adverse effects resolved soon after discontinuing these medications and adequate hydration. Clinicians should be cautious about neurological and renal adverse effects.
心境稳定剂锂盐与非典型抗精神病药物利培酮联合使用,广泛用于治疗精神障碍。关于二者联合使用导致多个器官系统出现严重药物不良反应的报道较为罕见。我们报告了1例患者在联合使用锂盐和利培酮后出现神经毒性和肾毒性的情况。
一名55岁男性在51岁时被诊断为分裂情感性障碍。他最初接受锂盐与奥氮平(每日5至15毫克)联合治疗,持续2年。53岁时,他因伴有精神病性特征的躁狂发作入住精神科病房。由于血糖控制不佳,我们将每日20毫克奥氮平换为每日4.5毫克利培酮,并联合每日900毫克锂盐。几天后,患者出现神经毒性、类神经阻滞剂恶性综合征症状以及肾毒性,血肌酐升高,尿量减少。在停用所有药物并给予生理盐水补液后,这些症状在2天内完全恢复。随后,我们重新给予较低剂量的锂盐(每日600毫克)和利培酮(每日3毫克),3天后再次出现类似情况。所有药物再次停用,1天后他的谵妄症状消失,异常数据恢复正常。最后,患者接受每日2毫克利培酮单药治疗,在接下来的2年中未再出现神经毒性和肾毒性情况。
该病例体现了锂盐和利培酮联合使用后的神经毒性和肾毒性。停用这些药物并充分补液后,这些不良反应很快得到缓解。临床医生应警惕其对神经和肾脏的不良反应。